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A simple, robust and reliable reversed phase HPLC method was developed and validated for the simultaneous 
determination of Trimethoprim (TMP), Sulfadimidine sodium (SDMS) and Tylosin tartrate (TYT) in Nuroprim® 
injectable solution formulation. The desired separation was achieved on XBridge C18 column (150  4.6 mm i.d., 
5m) at room temperature. The optimized mobile phase consisted of a binary solvent mixture of acetonitrile and 
aqueous triethylamine (TEA) solution adjusted to pH 5.7 by acetic acid.  The mobile phase flow rate was fixed at 
1.0 ml/min and the analytes were monitored at 287 nm using photodiode array detector. The effects of the 
chromatographic conditions on peaks capacity factor, USP tailing factor, column efficiency and resolution were 
systematically optimized. The method was validated as per International Conference of Harmonization (ICH) and 
United States Pharmacopeia (USP) guidelines and found to be adequate for the routine quantitative determination 
of TMP, SDMS and TYT in commercially available Nuroprim® injectable solution dosage form. 
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INTRODUCTION 
 
Nuroprim® injectable solution is a veterinary drug that 
is manufactured in Palestine and combines three antibacterial 
substances, namely Trimethoprim (TMP), Sulfadimidine sodium 
(SDMS) and Tylosin tartrate (TYT). Figure 1 shows the chemical 
structure of the three active pharmaceutical ingredients (APIs).  
Pharmacopoeial methods are available for the determination of 
each API individually. For example, an antibiotic microbial 
bioassay of TYT is official in BP and USP (British 
Pharmacopeia, 2013; United States Pharmacopeia, 2013), but it is 
considered to be neither accurate nor precise. The assay of TMP 
is official in BP and USP (British Pharmacopeia, 2013; United 
States Pharmacopeia, 2013), whereas sulfadimidine is only 
official in BP (British Pharmacopeia, 2013). The combined 
simultaneous analysis of the three APIs has not been adopted in 
any  official  pharmacopoeias. However, there are several HPLC 
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and LC-MS methods that have been reported for the quantitative 
determination of TMP, SDMS and TYT either alone or in 
combination (Solliec et al, 2014; Kotha et al, 2014; Ghanem et al, 
2013). According to intensive literature survey, there is no HPLC 
method yet reported on the simultaneous determination of the three 
APIs in any pharmaceutical formulation. Therefore, there is a need 
to develop a new validated quality control HPLC method to 
simultaneously determine TMP, SDMS and TYT in Nuroprim® 
injectable solution. The proposed method is aimed to separate the 
three active drugs from each other and from the excipients. It was 
validated as per ICH/USP guidelines validation norms (ICH, 2005; 
United States Pharmacopeia, 2013). 
 
MATERIALS AND METHODS 
 
Materials and reagents 
USP reference standards of trimethoprim                          
(TMP) (Lot: L0M053, Assay 99.9%) and tylosin tartrate (TYT) 
(Lot: F0D333, dried in vacuum at pressure not exceeding                
5mm of mercury at 60°C for 3 hours before usage) were utilized. 
Reference standard of sulfadimidine sodium (SDMS) was 
purchased from Nanhai Beisha Pharmaceutical Co., ltd (China). 
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Glacial acetic acid, triethylamine (TEA), and HPLC 
grade acetonitrile (ACN) solvent were purchased from Merck 
(Germany). High Purified water was prepared by using a Millipore 
Milli-Q plus water purification system. Nuroprim® injectable 
solution samples (labeled claim: each ml contains 25 mg TMP, 
140 mg SDMS and 112.5 mg TYT), all the APIs and excipients 
used in the manufacturing combination were kindly supplied by 
Pharmacare pharmaceutical company, Palestine. 
 
HPLC system  
Chromatographic analysis was carried out using a 
Dionex-Ultimate 3000 HPLC system equipped with an LPG-
3400SD pump, WPS-3000SL autosampler, TCC-3000 column 
oven, and DAD-3000 UV–VIS diode array detector. Chromeleon 
Data system Software (Version 6.80, DU10A Build 2826, 171948) 
was used for all the data acquisitions and analysis.  The search for 
suitable wavelength was achieved by using a double beam 
ultraviolet-visible spectrometer (PG Instruments, United 
Kingdom). 
 
Chromatographic conditions 
The HPLC experimental conditions were optimized on 
octadecyl silane C18 chemically bonded column (XBridge C18, 
5µm, 4.6 x 150 mm).  The aqueous mobile phase was prepared by 
diluting 2 ml of TEA in highly purified water up to 1000 ml, 
adjusted to pH 5.7 with glacial acetic acid, then filtered by using 
0.45 m microporous PVDF filter and was degassed by sonication 
prior to use. 
The gradient program was started at 5% acetonitrile, 95% 
TEA solution at pH 5.7, and then it was increased linearly up to 
35% acetonitrile during 10 minutes.  The acetonitrile was then 
increased to 55% acetonitrile and stayed there for one minute.  
Then mobile phase receded back to its initial percentages in one 
minute and remained for extra 4 minutes to ensure equilibrium 
achievement.   The optimized chromatographic conditions were 
1ml/min for flow rate, 287 nm as optimal wavelength, 25oC 
column thermostated temperature and 20µl injection volume.  
 
Preparation of standard solution 
The standard solution for the three drugs was prepared by 
dissolving 25 mg TMP reference standard, 140 mg SDMS 
reference standard and 112.5 mg TYT reference standard in 170 
ml of diluent (50% ACN), shaken by mechanical means for 5 
minutes, sonicated for two minutes and then diluted up to 200 ml 
with the same diluent. This solution was filtered using 0.45 m 
PVDF membrane filter before analysis. The obtained final solution 
contained 125µg/ml TMP, 700µg/ml SDMS and 562.5 µG/ML 
TYT. This solution was directly protected from light.  
 
Preparation of sample solution  
One ml of commercial Nuroprim® injectable solution was 
transferred to 200 ml volumetric flask containing 80 ml of diluent, 
shaken by mechanical means for 5 minutes, sonicated for two 
minutes and then diluted up to 200 ml with the same diluent. This 
solution was filtered using 0.45 m PVDF membrane filter before 
analysis. The obtained final solution contained 125µg/ml TMP, 
700µg/ml SDMS and 562.5µg/ml TYT. This solution was directly 
protected from light. 
 
RESULTS AND DISCUSSION 
 
Method development and Optimization 
The main aim of this study is to develop a simple and 
reliable method that could resolve TMP, SDMS and TYT from 
each other and from the placebo. Furthermore, the sought after 
method has to be used routinely in quality control laboratory at a 
relatively short time. To achieve this goal, several factors that play 
a significant role in RP-HPLC development including mobile 
phase percentage, pH and additives was tried.  Firstly, overlaid 
ultraviolet absorption spectra of TMP, SDMS and TYT (0.05 
mg/ml each) demonstrated that they shared a wavelength near to 
287 nm, and therefore it was selected in the entire study.  
 
 
 
TYT 
 
Fig. 1: Chemical structure of TMP, SDMS and TYT active ingredients. 
 
The initial mobile phase tested was an isocratic 
combination of water: acetonitrile (70:30; v/v) adjusted to pH of 
5.5 using 0.1N acetic acid. The resulted TMP, SDMS and TYT 
peaks were very broad with a USP-tailing factor of more than 2.5. 
Therefore, different percentages of 0.05%, 0.1%, 0.15% and 0.2% 
triethylamine (TEA) additive adjusted at pH of 5.7 by 0.1N acetic 
acid were tested to reduce the drugs band broadening and to 
increase selectivity. It was noticed that using 0.2% TEA solution at 
pH 5.7 sharpens the peaks to which the tailing factor values were 
less than 1.3. Three different pH values of 0.2% TEA aqueous 
solution at 5.5, 5.7, and 5.9 were tested and the optimal pH was at 
5.7. It was also noticed that increasing acetonitrile percentage 
decreased resolution between TMP and SDMS but improved TYT 
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peak shape. Therefore, a gradient elution was used to better control 
acetonitrile content during the chromatographic run, which only 
lasted about 13 minutes.  
Figure 2 shows a typical chromatogram of the placebo 
used, which contains purified water, propylene glycol and 
glycerol. Figure 3 shows a typical HPLC chromatogram of freshly 
prepared mixture of TMP, SDMS and TYT using the above-
mentioned optimized conditions. 
 
 
Fig. 2: Zoomed view of typical placebo chromatogram (water, propylene 
glycol and glycerol) using the optimized chromatographic conditions.   
 
 
Fig. 3: Typical chromatogram of a standard mixture of 125µg/ml TMP (8.117 
minutes), 700 µg/ml SDMS (9.760 minutes) and 562.5 µg/ml TYT (13.218 
minutes) using the optimized chromatographic conditions. 
 
Method Validation 
The ICH/USP guidelines were adopted in the entire 
study. Parameters such as system suitability, selectivity, sensitivity 
(LOD and LOQ), linearity, range, accuracy (recovery), precision 
(repeatability and intermediate precision) and robustness were all 
validated. 
 
System suitability 
The first step of the validation was testing the system 
suitability by injecting six successive replicates of the standard 
solutions and analyzing each active ingredient for its peak area, 
peak USP tailing factor, resolution, number of theoretical plates 
and capacity factor. The system suitability results for a combined 
solution of 125 µg/ml TMP, 700 µg/ml SDMS and 562.5 µg/ml 
TYT were calculated and revealed RSD % of less than 1.0% for all 
peaks areas. This method meets the accepted requirements as 
shown in table 1. 
Table 1:  Summary of the accepted system suitability requirements.  
Parameter TMP SDMS TYT Accepted limit 
% RSD 0.98 0.76 0.87  2.0% 
Tailing factor (Tf) 1.04 1.36 1.24  2.0 
Resolution (Rs) --- 3.85 8.47 ≥2.0 
Number of theoretical plates (N) 8017 5869 18876 ≥2000 
Capacity factor (k') 3.3 4.2 8.3 ≥2.0 
 
Selectivity (placebo interference)  
The same wavelength of 287 nm was used on placebo, 
standards and sample test solutions to assure the selectivity of the 
optimized method. The retention times of TMP, SDMS and TYT 
in sample solutions and in the standard solutions were identical. 
Figures 2 and 3 showed that there are no interferences at the 
retention time of TMP, SDMS and TYT due to placebo presence. 
Therefore, the proposed method is suitable for the quantification of 
the active ingredients in Nuroprim® Injectable solution.  
 
Sensitivity 
The sensitivity of the method was examined through 
measuring the limit of detection (LOD) and the limit of 
quantitation (LOQ) for TMP, SDMS and TYT at a signal-to-noise 
ratio of 3 and 10 respectively. This has been achieved by injecting 
a series of diluted solutions with known concentrations.  LOD was 
found to be 1.25, 7.0 and 5.6 µg/ml for TMP, SDMS and TYT 
respectively. LOQ was found to be 4.2, 23.3 and 18.7 µg/ml for 
TMP, SDMS and TYT respectively with RSD (n=3) of 4.9%, 
2.9% and 2.5% for TMP, SDMS and TYT respectively (accepted 
value is less than 10%). 
 
Linearity and range 
Calibration curves were constructed by injecting different 
amounts of TMP, SDMS and TYT in the range of 60% to 140% of 
the labeled amount (5 concentration levels and 3 replicates each) 
spiked to Nuroprim® placebo (water, propylene glycol and 
glycerol).  
The linearity in the range of 75-175 µg/ml, 420-980 
µg/ml and 337.5-787.5 µg/ml for TMP, SDMS and TYT was 
investigated respectively. The regression lines demonstrated 
linearity in the tested range. The regression analysis confirmed that 
the deviation of the y-intercept from zero is not significant; and the 
regression lines were linear with R2 of 0.9999, 0.9997 and 0.9996 
for TMP, SDMS and TYT respectively. The summary of the 
regression statistics is shown in table 2. 
 
Table 2:  Regression statistics. 
 
Active 
ingredient 
Linearity 
range 
(µg/ml) 
(R2 ) Linearity equation* 
Y-
intercept 
(%)  
TMP  75-175 0.9999 Y=431.1 X+320.1 0.59% 
SDMS  420-980 0.9998 Y=346.72X+747.9 0.30% 
TYT 337.5-787.5 0.9996 Y=178.84X+974.1 0.96% 
*Y is the dependent variable and X is the independent variable 
 
Accuracy (recovery) 
Accuracy was determined by the recovery study of 
known amounts of TMP, SDMS and TYT standards spiked to a 
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placebo matrix for injectable dosage form. Different 
concentrations of the three active ingredients were spiked to 
placebo matrix and the recovery was measured. The accuracy as 
reflected from recovery data for the three active ingredients is 
listed in Table 3.  The average recovery data of TMP ,SDMS and 
TYT showed results between 98.5% and 101.4% with % RSD of 
less than 1.3%, which are within the acceptable limit of (98.0 to 
102.0% recovery and %RSD of not more than 2.0%).  
 
Table 3:  Average recoveries, % RSD values at five concentration levels of 
spiking of TMP, SDMS and TYT. 
 
Active 
ingredient 
Amount added              
(level %) 
Avg. recovery (%) ± 
S.D  (n=3) 
RSD (%) 
(n=3) 
TMP 
75 µg /ml (60%) 98.8 ± 1.04 1.05 
100 µg /ml (80%) 100.3 ± 1.28 1.28 
125 µg /ml (100%) 99.8 ± 0.83 0.83 
150 µg /ml (120%) 101.4 ± 0.96 0.95 
175 µg /ml (140%) 98.8 ± 0.91 0.92 
SDMS 
420 µg/ml (60%) 100.1 ± 0.87 0.87 
560 µg/ml (80%) 100.8 ± 0.85 0.84 
700 µg/ml (100%) 98.6  ± 0.89 0.90 
840µg/ml (120%) 99.3 ± 0.97 0.98 
980 µg/ml (140%) 98.9 ± 0.84 0.85 
TYT 
337.5 µg/ml (60%) 98.9 ± 1.08 1.09 
450µg/ml (80%) 99.6 ± 0.95 0.95 
562.5 µg/ml (100%) 99.2  ± 0.83 0.84 
675µg/ml (120%) 98.8 ± 1.02 1.03 
787.5 µg/ml (140%) 98.5 ± 0.81 0.82 
 
Precision 
Repeatability 
One laboratory analyst carried out the assay of TMP, 
SDMS and TYT on six determinations of homogeneous sample of 
Nuroprim® injectable solution at 100% level of the test 
concentration with the same analytical equipment at the same day.  
The intraday assay results and statistical evaluation for assay of the 
three active ingredients showed RSD % values of 1.32%, 0.97% 
and 1.16% for TMP, SDMS and TYT respectively, which are 
within the acceptable limit of 2.0%.  
 
Intermediate Precision (ruggedness) 
Two laboratory analysts carried out the assay of TMP, 
SDMS and TYT on twelve homogeneous samples of Nuroprim® 
injectable solution at 100% level of the final test concentration 
with two different analytical equipments on two different days. 
The interday assay results and statistical evaluation for assay of the 
three active ingredients reveals RSD % values of 1.58%, 1.14% 
and 1.28% for TMP, SDMS and TYT respectively, which are 
within the acceptable limit of 2.0%. The results of the assay of the 
three ingredients proved that the method is repeatable and rugged 
enough for day-to-day use.   
 
Robustness 
Deliberate variations were performed in critical 
experimental conditions of the RP-HPLC method to assess its 
robustness. The five variations enforced to the chromatographic 
method are summarized in Table 4.  The modifications include 
different mobile phase flow rates of 0.9, 1.0, and 1.1 ml/min and 
three different column temperatures in the range 15-30C.  
Different TEA percentages (in the range of ± 5 of the nominal 
value and the normal TEA %) was also investigated. Finally, three 
different pH values of the buffer at 5.5, 5.7, and 5.9 were tested 
along with different column batches. The RSD % values showed 
no significant change in the final assay results of each of the above 
two ingredients using the five variations (Table 4). 
 
Table 4:  Robustness testing of the two active ingredients of TMP, SDMS and 
TYT 
Active 
ingredient 
Parameter 
Average assay% ± S.D 
(n=3) 
TMP 
0.9ml/min flow  
1.0ml/min flow 
1.1ml/min flow 
95% TEA 
100% TEA 
105% TEA 
5.5 pH buffer 
5.7 pH buffer 
5.9 pH buffer 
Temperature (15oC) 
Temperature (25oC) 
Temperature (30oC) 
Different columns  
99.4 ±0.83 
98.9 ±0.76 
99.8 ±0.94 
100.1± 1.06 
99.7±1.12                  
98.7 ±0.86 
100.4 ±0.79 
100.1 ±1.06 
99.8 ±0.81 
99.1 ±1.13 
99.3 ±0.97 
100.7 ±0.74 
99.4 ±1.46 
SDMS 
0.9ml/min flow  
1.0ml/min flow 
1.1ml/min flow 
95% TEA 
100% TEA 
105% TEA 
5.5 pH buffer 
5.7 pH buffer 
5.9 pH buffer 
Temperature (15oC) 
Temperature (25oC) 
Temperature (30oC) 
Different columns  
100.6 ±1.02 
99.4 ±1.15 
99.3 ±0.86 
99.2± 1.08 
98.5±0.68                  
99.4 ±0.78 
100.7 ±0.93 
101.2 ±0.84 
99.5 ±0.88 
98.6 ±0.73 
98.9 ±0.92 
100.8 ±1.09 
100.3 ±1.38 
TYT 
0.9ml/min flow  
1.0ml/min flow 
1.1ml/min flow 
95% TEA 
100% TEA 
105% TEA 
5.5 pH buffer 
5.7 pH buffer 
5.9 pH buffer 
Temperature (15oC) 
Temperature (25oC) 
Temperature (30oC) 
Different columns  
99.1 ± 0.93 
100.2 ±1.06 
99.3 ±0.74 
99.8± 1.08 
101.3±1.01                  
100.7 ±1.14 
100.6 ±0.86 
101.4 ±0.78 
99.4 ±0.83 
101.2±0.67 
99.3 ±0.85 
99.1 ±1.11 
99.7 ±1.26 
 
Applicability of the method to marketed products: 
In the local market, there is only one injectable dosage 
form that is commercially available (Nuroprim® injectable 
solution). The validated method is applied to the commercially 
available package as shown in Table 5. This acceptable value 
indicated the applicability of the proposed method for the routine 
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quality control of Nuroprim® Injectable solution without 
interference with the excipients. This was evidenced from the good 
actual results obtained as compared to the labeled claim 
percentages as well as the absence of any other peaks in the 
chromatogram of the injectable solution. 
 
Table 5:  Result of market product (Nuroprim® injectable solution). 
Product 
Name 
Labeled claim 
(mg/ml) 
TMP 
(mg/ml) 
SDMS 
(mg/ml) 
TYT 
(mg/ml) 
Nuroprim® 
Injectable 
solution 
TMP (25), 
SDMS (140) 
TYT (112.5) 
25.4 138.2 110.8 
 
CONCLUSION 
 
A novel validated RP-HPLC method was developed for 
the quantitative quality control determination of TMP, SDMS and 
TYT in nuroprim® injectable solution. It was evaluated for system 
suitability, selectivity, sensitivity, linearity, range, accuracy 
(recovery), precision (repeatability and intermediate precision) and 
robustness. The method proved to comply with ICH/USP 
guidelines and specifications. The method is rapid, accurate, 
precise and simple for the simultaneous determination of the 
combined TMP, SDMS and TYT in nuroprim® injectable solution 
in the presence of excipients.  
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